CATX
Perspective Therapeutics, Inc.
NYSE American · usd
Perspective Therapeutics, Inc. (CATX) trades at $1.19 (-26.10%) as of 1:51:31 PM EDT on Oct 26, 2026, -52.78% over the past month. Market cap is $183.78M, with 5.5 days to cover in short interest.
Stock performance
How Perspective Therapeutics, Inc. (CATX) stock has performed from one day to one year, with its 52-week range.
- 1D
- -26.09%
- 1W
- -45.66%
- 1M
- -52.78%
- YTD
- -56.73%
- 1Y
- -61.61%
- 52-wk range
- $1.12 – $6.16
Key statistics
Today's trading snapshot for CATX: day range, open, previous close, volume and market cap.
- Day range
- $1.12 – $1.59
- Open
- $1.40
- Prev close
- $1.61
- Volume
- 7.4M
- Market cap
- $183.78M
- Shares out
- 114.15M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Perspective Therapeutics, Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 449.35
- P/B
- 0.57
- P/FCF
- —
- ROE
- -35.9%
- ROA
- -29.7%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Oct 23, 2026
8-K filings
Material corporate events Perspective Therapeutics, Inc. has disclosed to the SEC on Form 8-K.
- Clinical trial resultsOct 23, 2026
On October 23, 2026, Perspective Therapeutics, Inc. issued a press release and posted to its website a presentation announcing updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for the treatment and diagnosis of patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors.
- Regulatory decisionOct 8, 2026
On October 8, 2026, Perspective Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration granted Fast Track Designation for the development of PSV359 for adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein-positive solitary fibrous tumors.
- Investor presentationOct 1, 2026
On October 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
- Partnership or collaborationSep 14, 2026
On September 14, 2026, Perspective Therapeutics, Inc. issued a press release announcing a clinical collaboration and supply agreement with Merck.
- Investor presentationSep 8, 2026
On September 8, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Dividend history and stock splits
Perspective Therapeutics, Inc.'s recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-10Jun 17, 2024
CATX short interest
How heavily CATX is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 5.5
- Short interest
- 16.57M
- Avg volume
- 3M
As of · reported to FINRA twice monthly.
CATX news
The latest news and headlines about Perspective Therapeutics, Inc. (CATX).
- Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?positiveZacks Investment Research· Oct 9, 2026
- Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in MelanomapositiveGlobeNewswire Inc.· May 21, 2026
- Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsightpositiveGlobeNewswire Inc.· Apr 20, 2026
- Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual MeetingpositiveGlobeNewswire Inc.· Apr 20, 2026
- Perspective Therapeutics to Participate in Upcoming Investor ConferencespositiveGlobeNewswire Inc.· Apr 2, 2026
Frequently asked questions
What is the Perspective Therapeutics, Inc. (CATX) stock price today?
Perspective Therapeutics, Inc. (CATX) is trading at $1.19 (-26.10% on the day) as of 1:51:31 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Perspective Therapeutics, Inc.?
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful…
What is the short interest in CATX?
As of Sep 30, 2026, CATX has 16.57M shares short and 5.5 days to cover.
What exchange is CATX listed on?
Perspective Therapeutics, Inc. (CATX) trades on NYSE American in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of CATX with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a CATX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.